News Clover Biopharmaceuticals, Ltd.

Equities

2197

KYG2280A1076

Market Closed - Hong Kong S.E. Other stock markets 01:38:42 28/06/2024 pm IST			5-day change	1st Jan Change
0.34 ^HKD	-1.45%		-6.85%	-45.16%

18/06	Clover Biopharmaceuticals’ SCB-1019 Shows Positive Results for Older Adult and Elderly Cohort	MT
18/06	Clover Biopharmaceuticals, Ltd. Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Clover Announces Positive Preliminary Phase Results for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults	19/06	AQ
Clover Biopharmaceuticals’ SCB-1019 Shows Positive Results for Older Adult and Elderly Cohort	18/06	MT
Clover Biopharmaceuticals, Ltd. Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults	18/06	CI
Clover Announces Positive Preliminary Phase Ⅰ Results for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults	18/06	PR
Clover Biopharmaceuticals, Ltd. announced that it has received $0.320713 million in funding	12/04	CI
Clover Biopharmaceuticals' RSV Vaccine Candidate Shows Promise in Early Trial	08/04	MT
Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort	08/04	PR
Clover Biopharmaceuticals, Ltd. Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 In Initial Young Adult Cohort	08/04	CI
Clover Biopharmaceuticals, Ltd. announced that it expects to receive $0.320713 million in funding	02/04	CI
Clover Biopharmaceuticals Trims Losses in 2023	27/03	MT
Clover Biopharmaceuticals, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
Sinovac Halts Production of COVID-19 Vaccine as Demand Wanes	12/01	MT
Clover Announces Positive Phase ? Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia (CIT)	29/12	AQ
Clover Biopharmaceuticals Publishes Positive Results from SCB-219M Clinical Trial	29/12	MT
Clover Biopharmaceuticals, Ltd. Announces Positive Phase I Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia	29/12	CI
Clover Biopharmaceuticals Completes Patient Enrollment for Australia Phase 1 Trial; Shares Fall 5%	13/12	MT
Clover Initiates Phase Ⅰ Clinical Trial for RSV Vaccine Candidate	13/12	PR
Clover Biopharmaceuticals, Ltd. Initiates Phase Clinical Trial for RSV Vaccine Candidate	13/12	CI
Clover Biopharmaceuticals Completes Submission of Application for Seasonal Flu Vaccine in Brazil	07/11	MT
Clover Biopharmaceuticals, Ltd. Completes Biologic License Application for Its Seasonal Influenza Vaccine in Brazil	07/11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Clover Biopharmaceuticals, Ltd.

Equities

2197

KYG2280A1076

Summary

Filters